Table 1.
Compiled results from major CD19-targeted CAR studies
| CLL/NHL | Preconditioning? | n | Treatment response | ||||
|---|---|---|---|---|---|---|---|
| CR | PR | SD | No response/PD | Persistence | |||
| Porter et al., (UPenn, 2015) (33) | (+) | 14 | >4 years | ||||
| Includes 3 patients from 2011 cohorts (34,35) | 14 CLL | 4/14 | 4/14 | – | 6/14 | ||
| mCD19_41BBζ construct | |||||||
| Brentjens et al., (MSK 2011) (36) | 8 CLL | Up to 30 days | |||||
| mCD19_CD28ζ construct | None | 4 CLL (1 passed from sepsis) | – | – | – | 4/4 | |
| (+) | 4 CLL | – | 1/4 | 2/4 | 1/4 | ||
| Kochenderfer et al. (NCI, 2012) (37) | (+) & IL-2 | 8 | Up to 132 days | ||||
| mCD19_CD28ζ construct | 4 CLL | 1/4 | 2/4 | 1/4 | – | ||
| 3 FL (1s treatement, 1 passed from flu) | – | 2/3 | – | – | |||
| 1 SMZL | – | 1/1 | – | – | |||
| Kochenderfer et al. (NCI, 2013) (38) | None | 10 | Up to 30 days | ||||
| mCD19_CD28ζ construct | 4 CLL | 1/4 | – | 1/4 | 2/4 | ||
| 2 DLBCL | – | – | 2/2 | – | |||
| 4 MCL | – | 2/4 | 2/4 | – | |||
| Kochenderfer et al. (NCI, 2015) (39) | (+) | 15 | Up to 60 days | ||||
| mCD19_CD28ζ construct | 4 CLL | 3/4 | 1/4 | – | – | – | |
| 1 SMZL | – | 1/1 | – | – | |||
| 4 PMBCL (1 Death) | 2/4 | – | 1/4 | – | |||
| 5 DLBCL (1 lost to follow-up) | 2/5 | 2/5 | – | – | |||
| 1 Low-grade NHL | 1/1 | – | – | – | |||
| Cruz et al. (NCI, 2013) (40) | None | 8 | Up to 84 days | ||||
| mCD19_CD28ζ construct in VSTs | 4 CLL | – | 1/4 | 1/4 | 2/4 | ||
| B-ALL | Preconditioning? | n | Treatment response | ||||
| MRD- | MRD+ | SD | No response/PD | Persistence | |||
| Cruz et al. (Baylor, 2013) (40) | None | 4 Adult ALL | Up to 84 days | ||||
| mCD19_CD28ζ construct in VSTs | 4 (2 in CR at the time of treatment) | 1/4 | – | – | 1/4 | ||
| Davila et al. (MSK 2014) (41) | (+) | 16 Adult ALL | Up to 3 months | ||||
| Includes Brentjens et al. (2011 Cohort) (36) | 8 with Refractory BM blasts | 7/8 | – | – | 1/8 | ||
| Includes Brentjens et al. (2013 Cohort) (42) | 5 MRD+ following salvage chemotherapy | 4/5 | 1/5 | – | – | ||
| mCD19_CD28ζ construct | 2 MRD− following salvage chemotherapy | 2/2 | – | – | – | ||
| 1 with Extramedullary disease | – | – | – | 1/1 | |||
| Maude et al. (UPenn 2014) (43) | (+) | 30 (25 Pediatric, 5 Adult) | Up to 12 months | ||||
| Includes Grupp et al. (2013 Cohort) (44) | 27 Patients with morphologic CR | 23/25 | 2/25 | – | – | ||
| (25 assessed for MRD) | |||||||
| mCD19_41BBζ construct | |||||||
| Lee et al. (NCI 2015) 45) | (+) | 20 Pediatric and young adult | Up to 42 days | ||||
| mCD19_CD28ζ construct | 20 ALL with Measurable Disease | 12/20 | 2/20 | 3/20 | 3/20 | ||
FL: follicular lymphoma; MCL: mantle cell lymphoma; PMBCL: primary mediastinal large B-cell lymphoma; SD: stable disease; SMZL: splenic marginal-zone lymphoma.